Last reviewed · How we verify

NCT05003063

Effects of Acetylcholine and Attention on Visual Spatial Representations in the Brain

Completed EARLY_PHASE1 Last updated 12 August 2021
What this trial tests

EARLY_PHASE1 trial testing Donepzil in Visual Perception in 12 participants. Completed in 2 August 2021.

Timeline
4 February 2021
Primary endpoint
2 August 2021
2 August 2021

Quick facts

Lead sponsorUniversity of California, Berkeley
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposebasic science
Enrollment12
Start date4 February 2021
Primary completion2 August 2021
Estimated completion2 August 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of California, Berkeley

Who can join

Adults 18 to 80, any sex, with Visual Perception or Attention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study in, healthy human subjects using fMRI and MRS (magnetic resonance spectroscopy) characterizes, how attention and acetylcholine affect visual perception and the brain's representation of the visual environment. Levels of acetylcholine in the cerebral cortex will be enhanced by administration of donepezil, an inhibitor of acetylcholinesterase. Half the subjects will receive donepezil and other half will receive placebo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Visual Perception

Currently open trials in the same condition.

Other University of California, Berkeley trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05003063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing